上海富雨生物科技有限公司
初级会员 | 第1年

18956075901

当前位置:上海富雨生物科技有限公司>>细胞库 / 细胞培养>>普通细胞>> HTh-7人甲状腺癌细胞 (附

HTh-7人甲状腺癌细胞 (附

参  考  价面议
具体成交价以合同协议为准

产品型号

品       牌

厂商性质生产商

所  在  地

更新时间:2025-02-11 18:16:53浏览次数:47次

联系我时,请告知来自 化工仪器网
同类优质产品更多>
人甲状腺癌细胞HTh-7 fromtheSham g rou p andModelgrou p were injectedwithsame amount ofnormalsaline ,1time/d , for2weeks

人甲状腺癌细胞HTh-7



fromtheSham g rou p andModelgrou p were
injectedwithsame amount ofnormalsaline ,
1time/d , for2weeks. Neurologicalimp airmentwasassessedby
Longa5-levelscale.
Blood-brainbarrier p ermeabilit y

Results: The cohort had a mean age of 39 years and included patients with severe polytrauma. Technical success was achieved in 95% of cases, with no intraoperative deaths or need for open surgical conversion. Perioperative complications were minimal, and the reintervention rate was 5.3%. This study evaluates 10 years of clinical experience managing TAI with TEVAR. Long-term follow-up, with a median duration of 29 months, revealed no graft-related complications or secondary interventions. Imaging confirmed sustained graft integrity, and clinical outcomes were favorable.

Conclusion: TEVAR is a reliable and effective treatment for traumatic aortic injuries, offering excellent technical success rates and minimal perioperative and long-term complications. This study highlights TEVARs advantages in managing polytrauma patients and its role as a minimally invasive alternative to open surgery. Additionally, the findings emphasize the need for comprehensive long-term follow-up protocols. Future research should aim to address challenges related to device durability and the integration of advanced imaging techniques to further enhance patient outcomes and broaden the applicability of TEVAR in trauma care.


会员登录

×

请输入账号

请输入密码

=

请输验证码

收藏该商铺

X
该信息已收藏!
标签:
保存成功

(空格分隔,最多3个,单个标签最多10个字符)

常用:

提示

X
您的留言已提交成功!我们将在第一时间回复您~
拨打电话
在线留言